WebinarsNew
Deep DiveNew
Explore Business Standard
Gold jewellery maker and exporter Rajesh Exports Ltd, currently under the regulator Sebi's scanner, on Wednesday said that of the several thousand clarifications sought by the regulator over the past two-and-a-half years, only nine remain unresolved - with the alleged Rs 15.15 lakh crore revenue inflation query being one of them. "All the other eight questions are minor. Even this ninth question is absolutely minor. SEBI has found certain things suspicious and needs more documents," said Rajesh Mehta, founder and Chairman of the company, told PTI in an interview. Sebi, in an interim order, held that Rajesh Exports inflated its consolidated revenues by Rs 15.15 lakh crore over FY21FY25 by attributing outsized revenues to overseas subsidiaries - particularly Switzerland-based Valcambi SA - despite the subsidiary's audited standalone financials showing only a fraction of those figures. The regulator flagged what it called a prima facie misrepresentation of the company's financial ...
Adani group companies reported a record capital expenditure of Rs 1.53 lakh crore (USD 16.1 billion) and an all-time high EBITDA of Rs 94,834 crore (USD 10 billion) in the 2025-26 fiscal year, underscoring an accelerating infrastructure expansion cycle while maintaining leverage below its stated target. The investment programme -- the largest annual capex undertaken by an Indian corporate group -- lifted the portfolio's gross asset base to Rs 7.85 lakh crore (USD 82.8 billion), with nearly 80 per cent of spending directed towards energy, utilities, transport, and logistics businesses. Consolidated EBITDA rose 5.6 per cent year-on-year, according to the group's annual results and credit compendium released on Tuesday. Nearly 80 per cent of FY26 investments were directed toward core infrastructure businesses, including energy, utilities, transport, and logistics, underscoring the group's continued focus on sectors linked to India's infrastructure build-out. The investment cycle comes
JK Lakshmi Cement expects its pre-tax earnings or EBITDA to improve in the fourth quarter and subsequent periods on the back of rising sales realisation and growing non-trade (B2B) volumes, its President & Director Arun Kumar Shukla said on Monday. Non-trade (Institutional) prices are firming up, demand remains strong, and costs are inching higher, which together will support better realisations compared to the December quarter. "So, EBITDA (earnings before interest, tax, depreciation and amortisation) will be better because institutional prices have gone up, demand is better, and cost is also going up. So, I think it is going to be better than Q3 realisation-wise," he said. Cement companies in their Q3 earnings have reported an impact on topline on account of softer cement prices due to GST reduction. When asked about the fourth quarter, Shukla said, "I see it (Q4/FY'26) good because volume and demand are good. Since cost has gone up, prices are also inching up. So, Q4 is going .
Livspace, which is in the home design and interiors sector, has posted a 23 per cent increase in revenue to Rs 1,460 crore during the last fiscal, helping the company trim losses to Rs 131 crore. In a statement on Monday, the company said it has posted a revenue of Rs 1,460 crore in FY25 and "a near-50 per cent reduction in adjusted EBITDA loss to approximately Rs 131 crore." The result reflects stronger traction in premium and mass-premium residential segments, higher quality of revenue, and ongoing discipline on costs and unit economics, the company added. Livspace provides a one-stop renovation solution for homeowners -- from design to managing last-mile ful?llment for all rooms in a home. The company has brought together designers, brands, manufacturers and contractors to enable an eCommerce-like experience. Livspace currently serves Singapore (through Qanvast) and over 70 metro and non-metro areas in India. The company has delivered over 120,000 rooms and has sold over 5 mil
Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian said in an analyst call. He noted that around USD 145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about USD 70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to